

Press Release



ASKA Pharmaceutical and Insud Pharma Have Entered into a New License Agreement

TOKYO, December 25, 2024 - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter "ASKA"), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), and Insud Pharma (Head Office: Madrid, Spain) have expanded their current collaboration by entering into a new license agreement that grants ASKA Pharmaceutical Co., Ltd. exclusive rights to develop and market a new product in the woman health field, the product of which is owned by Insud Pharma in Japan.

Under the terms of the agreement, ASKA will obtain the exclusive rights to develop and market the Drug in Japan. In consideration, ASKA will pay Insud Pharma an upfront payment upon execution of the agreement and milestone payments based on the development progress. Other details of the agreement are not disclosed. The impact of this transaction on the financial results for FY2024 is expected to be immaterial.

ASKA is strengthening its product lineup as a specialty pharma company in the field of obstetrics and gynecology. Through the agreement, we will make further contributions to improving women's health and quality of life.

Reference

Aside from this agreement, ASKA has released a license agreement with Insud Pharma dated January 8, 2020 for a cyclical dosing formulation (development code: LF111) consisting of drospirenone in a regimen of 24 days of 4 mg of drospirenone tablets followed by 4 days of placebo. ASKA has acquired the rights to develop and market this drug in Japan and Korea. In Japan, ASKA filed an application for manufacturing and marketing approval for the indication of contraception on June 24, 2024.

About Insud Pharma

Insud Pharma (<https://www.insudpharma.com/en/>) is a leading Spanish company with a track record in the pharmaceutical and healthcare industry spanning over 45 years. With 9,000 employees worldwide, Insud Pharma's contribution to global public health is enormous, thanks to the medicines and APIs developed and manufactured at its three highly synergic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience).

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp